FDA Seeks Active System for Monitoring Adverse Events - Expanded access to healthcare data will modernize drug-safety assessment and product development. - BioPharm International

ADVERTISEMENT

FDA Seeks Active System for Monitoring Adverse Events
Expanded access to healthcare data will modernize drug-safety assessment and product development.


BioPharm International
Volume 21, Issue 8

DISTRIBUTED NETWORK

This expansion of AERS, though, will not lead to any giant FDA health information database for postmarket surveillance. Instead, FDA will expand its oversight capabilities by accessing data on drug use, patient outcomes, and specific safety issues held by private health plans, database operators, government agencies, and manufacturers. The aim is to build a national, integrated, electronic network for monitoring medical product safety through contracts and partnerships with these existing information sources. By using a distributed network, all the personal medical data remains behind firewalls, reducing concerns about the FDA compromising patient privacy and data security.

The FDA has been laying the foundation for the Sentinel System for years through such arrangements with healthcare "data owners" that permit it to pose specific questions for evaluation through electronic health records, claims databases, and other information sources. For example, the FDA has contracted for several years with UnitedHealth Group's Ingenix, Vanderbilt University, Kaiser Foundation Research Institute, and Harvard Pilgrim Health Care to access pharmacoepidemiologic information that can test hypotheses arising from AE reports.

The agency's Center for Biologics Evaluation and Research (CBER) works with the CDC, the Veterans Health Administration (VHA), the Centers for Medicare and Medicaid Services (CMS), and large health plans to monitor influenza vaccine use and related outcomes. A new CMS policy now gives FDA access to one billion pharmacy claims a year collected by the Part D Medicare drug-benefit program, a treasure trove of pharmaceutical usage data. With additional funds to support postmarket safety surveillance, FDA plans to expand its access to CMS, VHA, and health plan databases to further expand its ability to detect and assess adverse events related to marketed therapies.

This distributed network system is expected to operate under a charter that defines which entities may join the public–private partnership, what data sources will be used, what queries can be run on the system, who will be able to run queries, how specific evaluations will be paid for, and how privacy protection will be ensured. A nonprofit network convener will channel information and queries to the partnership and determine how results will be communicated to network participants and to the general public.

Many of these administrative and policy issues will be examined by an active surveillance pilot sponsored by the Pharmaceutical Research and Manufacturers of America (PhRMA). After more than a year in development, the project is being launched as a public–private partnership involving PhRMA, the FDA, and the Foundation for NIH, with Woodcock as chair. The aim is to test approaches for organizing and operating a drug-safety query system using a distributed information network.

STREAMLINING RESEARCH

An important gain from a more efficient and proactive postmarket surveillance system will be to facilitate FDA approval of new drug applications. If the regulators have confidence that safety problems will be identified more quickly and appropriately after a drug goes to market, they may be more willing to approve a market application for a therapy that raises some risk concerns.

Biopharmaceutical manufacturers are nervous that earlier and broader assessment of postmarket data will yield false negatives that set off alarms on every new product. But FDA officials believe that enhanced drug monitoring may even reduce the need for some postmarketing studies. Instead of requiring manufacturers to sponsor a long list of postmarket clinical studies, FDA reviewers may call for six months or a year of database monitoring for certain anticipated safety concerns. Expanded postmarket assessment may put to rest concerns about the safety of a new drug or vaccine that are raised in prelicensure studies, observed CBER Director Jesse Goodman; "The data can cut both ways."

Ultimately, it may be possible to monitor medical product safety through a national information network that connects clinicians, consumers, and providers across the healthcare system. A linked system would provide a broader picture of health problems and improve tracking of patients who shift healthcare providers, Woodcock commented at the Brookings forum. But that would raise privacy issues and require a higher level of consent and transparency, she noted "We would not do this to start," she said, "but we don't want to rule it out."

Effective communication about safety signals from interim results will be a challenge, as will efforts to provide adequate and sustained financial support for what will be a costly undertaking. But these are issues that the FDA and its Sentinel partners will address, as well as concerns related to scientific accuracy and data reliability, said von Eschenbach. FDA is not implementing the Sentinel System "solely because Congress told us to, but because it's the right thing to do," he asserted. "FDA must, will, and needs to do this."

Jill Wechsler is BioPharm International's Washington editor, Chevy Chase, MD, 301.656.4634,


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here